Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

A Phase I Study of Candidate Influenza Vaccines MVA-NP+M1 and ChAdOx1 NP+M1

14 dicembre 2015 aggiornato da: University of Oxford

A Phase I Study to Determine the Safety and Immunogenicity of Vaccination Regimens Employing the Candidate Influenza Vaccines MVA-NP+M1 and ChAdOx1 NP+M1

This will be a randomised observational phase 1 study in 48 healthy volunteers aged 18-50. The study is assessing safety and immunogenicity of viral vectored vaccines ChAdOx1 NP+M1 and MVA NP+M1 in heterologous prime-boost regimens. A crossover design will allow comparison of the two vaccines. Volunteers will be divided into 4 groups (n=12 in each group). Groups will be recruited simultaneously to control for seasonal changes in influenza. This is because at certain times of year there is likely to be a higher naturally acquired T cell response to influenza than at other times due to circulating influenza virus in the community.

The study has been extended to include 2 additional groups (group 5 & 6), each containing 12 healthy adults aged 50 years or above. Group 5 will receive ChAdOx 1 NP+M1 on day 0, and group 6 will receive this with an additional boost of MVA-NP+M1 8 weeks later.

Panoramica dello studio

Stato

Completato

Tipo di studio

Interventistico

Iscrizione (Effettivo)

72

Fase

  • Fase 1

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

      • Guildford, Regno Unito, GU2 7XP
        • Surrey Clinical Research Centre, University of Surrey
      • Southampton, Regno Unito, SO16 6YD
        • NIHR Wellcome Trust Clinical Research Facility Southampton
    • Oxfordshire
      • Oxford, Oxfordshire, Regno Unito, OX3 7LE
        • Centre for Clinical Vaccinology and Tropical Medicine

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria for Groups 1-4

The volunteer must satisfy all the following criteria to be eligible for the study:

  • Healthy adults aged 18 to 50 years
  • Able and willing (in the Investigator's opinion) to comply with all study requirements
  • Willing to allow the investigators to discuss the volunteer's medical history with their General Practitioner
  • For females only, willingness to practice continuous effective contraception during the study and a negative pregnancy test on the day(s) of vaccination
  • Agreement to refrain from blood donation during the course of the study
  • Provide written informed consent

Exclusion Criteria for Groups 1-4

The volunteer may not enter the study if any of the following apply:

  • Participation in another research study involving an investigational product in the 30 days preceding enrolment, or planned use during the study period
  • Previous receipt of any recombinant adenoviral or recombinant MVA vectored vaccine
  • Administration of immunoglobulins and/or any blood products within the three months preceding the planned administration of the vaccine candidate
  • Any confirmed or suspected immunosuppressive or immunodeficient state, including HIV infection; asplenia; recurrent, severe infections and chronic (more than 14 days) immunosuppressant medication within the past 6 months (inhaled/topical steroids are allowed)
  • History of allergic disease or reactions likely to be exacerbated by any component of the vaccine
  • Any history of anaphylaxis in reaction to vaccination
  • History of cancer (except basal cell carcinoma and cervical carcinoma in situ)
  • History of serious psychiatric condition
  • Any chronic illness requiring on-going or awaiting hospital specialist supervision, other than minor surgical procedures and follow up of surgery over 6 months prior to screening
  • Suspected or known current injecting drug or alcohol abuse (as defined by an alcohol intake of greater than 42 units every week)
  • Seropositive for hepatitis B surface (HBsAg) or hepatitis C virus (antibodies to HCV)
  • Pregnancy, lactation or willingness/intention to become pregnant during the study
  • Any other significant disease, disorder or finding (including blood test results), which, in the opinion of the Investigators, would either put the volunteer at risk because of participation in the study, or may influence the result of the study
  • No response / confirmation from GP regarding previous medical history

Inclusion Criteria for Groups 5-6

The volunteer must satisfy all the following criteria to be eligible for the study:

  • Healthy adults aged 50 or over, no upper age limit
  • Able and willing (in the Investigator's opinion) to comply with all study requirements
  • Willing to allow the investigators to discuss the volunteer's medical history with their General Practitioner
  • For women of child bearing potential only, willingness to practice continuous effective contraception (i.e. hormonal contraception, intrauterine device or barrier contraception) during the study and a negative urinary pregnancy test on the day(s) of vaccination
  • Agreement to refrain from blood donation during the course of the study
  • Provide written informed consent

Exclusion Criteria for Groups 5-6

The volunteer may not enter the study if any of the following apply:

  • Participation in another research study involving an investigational product in the 30 days preceding enrolment, or plans to participate during the study period
  • Previous receipt of a vaccine or plans to receive any vaccinations during the study that would interfere with the interpretation of the results of the trial
  • Administration of immunoglobulins and/or any blood products within the three months preceding the planned administration of the vaccine candidate
  • Any confirmed or suspected immunosuppressive or immunodeficient state, including HIV infection; asplenia; recurrent, severe infections and chronic (more than 14 days) immunosuppressant medication within the past 6 months (inhaled/topical steroids including eye drops and nasal spray/intra-articular steroid injections are allowed)
  • History of allergic disease or reactions likely to be exacerbated by any component of the vaccine including eggs or Kathon (a biocide added to body washes, conditioners, liquid soaps, shampoos and wipes as a preservative)
  • Any history of anaphylaxis in reaction to vaccination
  • History of treatment for cancer within the preceding six months (except basal cell carcinoma and cervical carcinoma in situ)
  • History of serious psychiatric condition
  • Any chronic illness requiring on-going or awaiting hospital specialist supervision, other than minor surgical procedures and follow up of surgery over 6 months prior to screening
  • Suspected or known injecting drug abuse within the last 5 years
  • Alcohol abuse (as defined by an alcohol intake of greater than 42 units every week)
  • Seropositive for hepatitis B surface antigen (HBsAg) or hepatitis C virus (antibodies to HCV) or HIV
  • Pregnancy, lactation or willingness/intention to become pregnant during the study
  • Any other significant disease, disorder or finding (including blood test results), which, in the opinion of the Investigators, would either put the volunteer at risk because of participation in the study, or may influence the result of the study
  • No response / confirmation from GP regarding previous medical history

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Prevenzione
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Group 2
ChAdOx1 NP+M1 2.5 x 10¹⁰vp followed by MVA NP+M1 1.5 x 10⁸pfu 52 weeks later.
MVA NP+M1 1.5 x 10⁸pfu intramuscularly.
ChAdOx1 NP+M1 2.5 x 10¹⁰vp intramuscularly.
Sperimentale: Group 3
MVA NP+M1 1.5 x 10⁸pfu followed by ChAdOx1 NP+M1 2.5 x 10¹⁰vp 8 weeks later.
MVA NP+M1 1.5 x 10⁸pfu intramuscularly.
ChAdOx1 NP+M1 2.5 x 10¹⁰vp intramuscularly.
Sperimentale: Group 4
MVA NP+M1 1.5 x 10⁸pfu followed by ChAdOx1 NP+M1 2.5 x 10¹⁰vp 52 weeks later.
MVA NP+M1 1.5 x 10⁸pfu intramuscularly.
ChAdOx1 NP+M1 2.5 x 10¹⁰vp intramuscularly.
Sperimentale: Group 1
ChAdOx1 NP+M1 2.5 x 10¹⁰vp followed by MVA NP+M1 1.5 x 10⁸pfu 8 weeks later.
MVA NP+M1 1.5 x 10⁸pfu intramuscularly.
ChAdOx1 NP+M1 2.5 x 10¹⁰vp intramuscularly.
Sperimentale: Group 5
ChAdOx1 NP+M1 2.5 x 10¹⁰vp
MVA NP+M1 1.5 x 10⁸pfu intramuscularly.
Sperimentale: Group 6
ChAdOx1 NP+M1 2.5 x 10¹⁰vp followed by MVA NP+M1 1.5 x 10⁸pfu 8 weeks later.
MVA NP+M1 1.5 x 10⁸pfu intramuscularly.
ChAdOx1 NP+M1 2.5 x 10¹⁰vp intramuscularly.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
To assess the safety of prime/boost vaccination regimens employing MVA-NP+M1 and ChAdOx1 NP+M1.
Lasso di tempo: Up to 78 weeks post first vaccination.
Safety will be assessed by the nature, frequency, severity, seriousness and duration of adverse events arising during the study combined with analysis of hematology and biochemistry lab tests for abnormalities.
Up to 78 weeks post first vaccination.

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
To assess the cellular immune response generated by prime/boost vaccination regimens employing MVA-NP+M1 and ChAdOx1 NP+M1.
Lasso di tempo: 78 weeks after first vaccination
The secondary outcomes of peak immune response after first vaccination and peak immune response after second vaccination will be analysed by calculating the area under the curve of the immune response (IFN-γ SFC/ million PBMCs) for each volunteer from baseline to week 78. The mean area under the curve in the 4 groups will then be compared using an analysis of variance, or in the case of skewed data a Kruskal Wallis test. Further pairwise comparisons will be made if a significant difference is found between groups.
78 weeks after first vaccination

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Investigatori

  • Investigatore principale: Adrian V S Hill, MD, University of Oxford

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio

1 aprile 2013

Completamento primario (Effettivo)

1 novembre 2015

Completamento dello studio (Effettivo)

1 novembre 2015

Date di iscrizione allo studio

Primo inviato

18 marzo 2013

Primo inviato che soddisfa i criteri di controllo qualità

21 marzo 2013

Primo Inserito (Stima)

26 marzo 2013

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Stima)

15 dicembre 2015

Ultimo aggiornamento inviato che soddisfa i criteri QC

14 dicembre 2015

Ultimo verificato

1 dicembre 2015

Maggiori informazioni

Termini relativi a questo studio

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Prove cliniche su MVA NP+M1

Sottoscrivi